Levy, B. Et Al. 2022.

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)& nbsp;

. LUNG CANCER , vol.166 , 107-113.

Levy, B., Barlesi, F., Paz-Ares, L., Bennouna, J., ERMAN, M., Felip, E., ... Isla, D.(2022).

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)& nbsp;

. LUNG CANCER , vol.166, 107-113.

Levy, Benjamin Et Al. "

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)& nbsp;

," LUNG CANCER , vol.166, 107-113, 2022

Levy, Benjamin Et Al. "

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)& nbsp;

." LUNG CANCER , vol.166, pp.107-113, 2022

Levy, B. Et Al. (2022) . "

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)& nbsp;

." LUNG CANCER , vol.166, pp.107-113.

@article{article, author={Benjamin Levy Et Al. }, title={

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)& nbsp;

}, journal={LUNG CANCER}, year=2022, pages={107-113} }